Randomized Control Trials

Apixaban 2.5 mg BID to prevent VTE after elective TKR surgeries: Superior efficacy without increased bleeding vs. subcutaneous enoxaparin 40 mg QD2

Mean duration of treatment was 12.1±3.2 days for Eliquis and 12.1±2.8 days for enoxaparin.2

Mean duration of treatment was 12.1±3.2 days for Apixaban and 12.1±2.8 days for enoxaparin. 2
*p values are one sided for superiority test of relative risk. 2

 

Apixaban 2.5 mg BID to prevent VTE after elective THR surgeries: Superior efficacy vs enoxaparin 40 mg QD with no significant increased risk of major bleeding3

The mean duration of treatment was 34.0±7.7 days in the Eliquis group and 33.9±7.8 days in the enoxaparin group.3

The mean duration of treatment was 34.0±7.7 days in the Apixaban group and 33.9±7.8 days in the enoxaparin group.3
*p values are two-sided for superiority test of relative risk. 3

 

ADVANCE-2: Apixaban versus Enoxaparin for Thromboprophylaxis after Knee Replacement; BID: twice daily; DVT: deep-  vein thrombosis; PE: pulmonary embolism; RRR: relative risk reduction; QD: once daily; SC: subcutaneous; TKR: total knee  replacement; THR: total hip replacement; VTE: venous thromboembolism.

References: 1 Granger CB, Alexander JH, McMurray JJ, et al. Apixaban  versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-992. 2. Lassen MR, Raskob GE, Gallus A, Pineo  G, Chen D, Hornick P; ADVANCE-2 investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement  (ADVANCE-2): a randomized double-blind trial. Lancet. 2010;375(9717):807-815. 3. Lassen MR, Gallus A, Raskob GE, Pineo  G, Chen D, Ramirez LM; ADVANCE-3 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement.  N Engl J Med. 2010;363(26):2487-2498.

#Ruff CT, et al. Lancet. 2014;383(9921):955-62, Hur et al, Acta Orthopaedica 2017; 88 (6): 634–641, Cohen AT et al. Adv Ther 2014;31:473-93

Disclaimer: The products discussed herein may have different product labeling in different countries. The product information provided in this site is intended only for residents of India

PP-ELI-IND-0967 28-07-2021
Please click on Prescribing Information link to view safety and adverse events information of Eliquis
For the use only of registered medical practitioner, or a hospital or a laboratory.